Do children have increased susceptibility for developing secondary acute myelogenous leukemia?
This study was undertaken to evaluate the effects of age on a child's susceptibility to developing leukemia following exposure to known leukemogenic agents. The clinical literature describing the risk of developing acute myelogenous leukemia (AML) following treatment with alkylating agents or topoisomerase reactive drugs (known leukemogens) was used as a basis for this investigation. Based on this preliminary assessment, the age of the child does not appear to be an independent variable for risk following treatment with either class of drug. Although the number of studies and cases was very small, the available scientific and medical literature does not support the hypothesis that children will necessarily have an altered susceptibility or increased risk of developing chemotherapy-induced AML.
Pyatt
David W
DW
University of Colorado Health Sciences Center, Molecular Toxicology and Environmental Health Sciences, 4200 East 9th Avenue, Denver, CO 80262, USA. dpyatt@summittoxicology.com
Hays
Sean M
SM
Cushing
Colleen A
CA
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D004198:Disease Susceptibility; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced / Q000453:epidemiology* / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000453:epidemiology* / Q000473:pathology; D059005:Topoisomerase II Inhibitors
D018906:Antineoplastic Agents, Alkylating; D059005:Topoisomerase II Inhibitors